It would be interesting to test if reduced nidogen-1 expression occurs in premetastatic niches and could therefore prepare ease-of-entry for later incoming cancer cells and investigate if these effects only occur in some organs (e.g. lungs) and not others (e.g. kidney). Here, NID1 is linked to cancer.